menu
    • menu
    [{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"AskGene Pharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ASKB589","moa":"||Claudin 18.2","graph1":"Oncology","graph2":"Phase III","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"AskGene Pharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ASKB589","moa":"||Claudin 18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"AskGene Pharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ASKG915","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"AskGene Pharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ASKG712","moa":"||VEGF receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"AskGene Pharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ASKG712","moa":"||VEGF receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Limertinib","moa":"||EGFR TK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aosaikang Pharmaceutical \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Aosaikang Pharmaceutical \/ Innovent Biologics"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Limertinib","moa":"||EGFR TK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Limertinib","moa":"||EGFR TK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aosaikang Pharmaceutical \/ Innovent Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Aosaikang Pharmaceutical \/ Innovent Biologics"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Limertinib","moa":"||EGFR TK","graph1":"Oncology","graph2":"Phase III","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aosaikang Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aosaikang Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Oncology","graph2":"Phase I","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aosaikang Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aosaikang Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ASKC202","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aosaikang Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aosaikang Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Propella Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Licensing Agreement","leadProduct":"Capsaicin","moa":"||TRPV1","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ASKB589","moa":"||Claudin 18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"AskGene Pharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ASKG315","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"AskGene Pharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ASKG315","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Aosaikang Pharmaceutical \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ASKC200","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Topical","sponsorNew":"Aosaikang Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aosaikang Pharmaceutical \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Aosaikang Pharmaceutical

    Menu

    Aosaikang Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Limertinib,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Innovent Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Innovent’s Limertinib Approved By NMPA for First-Line Lung Cancer Treatment

                            Details : ASK120067 (limertinib) is an oral third-generation EGFR TKI, approved by NMPA for the first-line treatment of adult patients with NSCLC harboring EGFR exon 19 deletions or exon 21 L858R mutations.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 25, 2025

                            Lead Product(s) : Limertinib,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Innovent Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Limertinib,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Innovent Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Innovent and ASK Pharm Announce NMPA Approval of Limertinib for Lung Cancer

                            Details : ASK120067 (limertinib) is an oral third-generation EGFR TKI with proprietary rights, approved by NMPA for the treatment of adults with locally advanced or metastatic EGFR T790M-mutated NSCLC.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 16, 2025

                            Lead Product(s) : Limertinib,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Innovent Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASKC200,Inapplicable

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Safety and Pharmacokinetics of ASKC200 in Osteoarthritic Knee Pain

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 26, 2024

                            Lead Product(s) : ASKC200,Inapplicable

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Limertinib,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Innovent Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Innovent And Ask Pharm Collaborate on Limertinib For Lung Cancer Treatment

                            Details : Under the agreement, Innovent will obtain the exclusive commercialization rights for limertinib, a third-generation EGFR inhibitor for the treatment of lung cancer, in mainland China.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 10, 2024

                            Lead Product(s) : Limertinib,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Innovent Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASKB589,Oxaliplatin,Capecitabine,Tislelizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : AskGene Pharma Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarci...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 16, 2024

                            Lead Product(s) : ASKB589,Oxaliplatin,Capecitabine,Tislelizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : AskGene Pharma Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASKG712,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Recipient : AskGene Pharma Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ASKG712 in Patients With Diabetic Macular Edema

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 11, 2023

                            Lead Product(s) : ASKG712,Inapplicable

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Recipient : AskGene Pharma Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASKG915,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : AskGene Pharma Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 22, 2023

                            Lead Product(s) : ASKG915,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : AskGene Pharma Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASKB589,Capecitabine,Oxaliplatin,Sintilimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : AskGene Pharma Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ASKB589 in Combination With CAPOX and Sintilimab in Patients With Advanced, and Unresectable G/GEJ Cancer.

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 01, 2022

                            Lead Product(s) : ASKB589,Capecitabine,Oxaliplatin,Sintilimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : AskGene Pharma Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifampicin,Limertinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            November 30, 2022

                            Lead Product(s) : Rifampicin,Limertinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed

                            Aosaikang Pharmaceutical

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASKG315,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : AskGene Pharma Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of ASKG315 in Patients With Advanced Solid Tumors.

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 26, 2022

                            Lead Product(s) : ASKG315,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : AskGene Pharma Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth